Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 28 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 28 versus TAYTULLA.
GENCEPT 10/11-28 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive